Author Archives: Warren Woessner

Amgen v. Sanofi – Invalidation Without Representation?

The End of the “Newly Characterized Antigen” Rule for Antibody Claims In Amgen, Inc. v. Sanofi, Appeal no. 2017-1480 (Fed. Cir., Oct. 5, 2017) the Fed. Cir. panel reversed the district court’s finding that Amgen antibody patents 8,289,165 and 8859741 … Continue reading

Posted in Written Description Requirements (WDR) | Leave a comment

Sea Change in IPR or Just an SOS? – Aqua Products, Inc. v. Matal

Sitting en banc, a fractured Federal Circuit (Appeal no. 2015-1177 (Fed. Cir., Oct. 4, 2017)) released 140+ pages comprising five separate opinions (7 Judges “concur in result”). The majority held that, at least under the current PTO regulations: “The only … Continue reading

Posted in 2016 Patent Review, 2017 Patent Review | Leave a comment

Sixteen Critical 2016-2017 Patentability & Validity Developments

This is a guest post from Donald Chisum and Janice Mueller of the Chisum Patent Academy. Below are highlights of the Critical  Patentability & Validity Developments of 2016-2017.   The Federal Circuit’s January 2017 decision in Sonix Tech. Co. v. Publications Int’l, … Continue reading

Posted in Patent Eligible Subject Matter | Leave a comment

Chisum Patent Academy

The Federal Circuit and Supreme Court Have Already Issued 100 Precedential Patent Opinions in 2017! Are You Up to Speed? Stay on top of the latest critical developments by joining us this spring in Houston or Cincinnati. The Chisum Patent … Continue reading

Posted in CLE, Conferences and Classes | Tagged , , , , , , , | Leave a comment